The New York-based startup Epibone intends to begin human testing on a procedure that will utilize stem cells to regenerate living bone tissue. The researchers, originally from Columbia University, will apply autologous [the patient’s own] stem cells to nanofiber scaffolding of the desired size and shape and direct the stem cells to differentiate into a physical and genetic replica of the patient’s own bone. Continue reading
In a recent study conducted by the University Of Texas Southwestern Medical Center, scientists have discovered a rare line of stem cells involved in regulating spermatogenesis [the production of sperm cells]. Furthermore, these stem cells are resistant to chemotherapy and radiotherapy, which are toxic to the male germline and common causes for male infertility. Continue reading
Researchers from the Mayo Clinic have joined the Army’s Afirm II [Armed Forces Institute of Regenerative Medicine] program. AFIRM spearheads a national consortium of advanced research centers developing regenerative medical therapies to care for and treat the injuries of severely wounded army veterans. Mayo Clinic researchers will focus on peripheral nerve regeneration. Continue reading
Thousands of people die each year waiting for an organ donor to save their lives.
Research coming forth each day is revealing that the promise of regenerative medicine, may one day aid in preventing needless loss of life due to lack of available donors.
Timothy Kieffer, Professor of Cellular and Physiological Sciences at the University of British Columbia [UBC], in conjunction with scientists from the New Jersey-based BetaLogics, recently put out research demonstrating that human stem cell transplants can successfully restore insulin production and reverse diabetes in mice.
The promise of regenerative medicine has taken another step toward fruition this past week with announcements inYokohama, Japan at the annual meeting of the International Society for Stem Cell Research (ISSCR) that two research groups are moving forward with human clinical trials. One will be focusing on a rare genetic neurological disease [Pelizaeus-Merzbacher disease (PMD) – a progressive and fatal disorder in which a genetic mutation inhibits the normal growth of myelin] and another for the loss of vision in elderly people [age-related macular degeneration (AMD)]
Researchers have been working to enhance the productive potential of autologous (a patient’s own) stem cells. In one study, a patient’s own stem cells were extracted and cultured to differentiate into heart tissue cells. These cultured stem cells were then implanted into the damaged heart tissue and were found to improve some of the symptoms of heart failure.
In a recent study published in the May issue of Neurosurgery, the journal of the Congress of Neurological Surgeons, patients suffering from permanent spinal cord injuries (paraplegia or quadriplegia) recovered significant motor function after receiving a treatment utilizing their own [autologous] mesenchymal stem cell (MSC).
Japanese researchers have successfully used autologous (a patient’s own) stem cells to grow new heart muscle tissue in order to treat heart disease. In the study, the researchers found that implanting this new tissue into damaged heart tissue resulted in overall improved heart function.
Cell Stem Cell recently published a new study headed by Principal investigator Songtao Shi, professor at the Ostrow School of Dentistry of USC Center for Craniofacial Molecular Biology. The study indicates that autoimmune disorders can be controlled through mesenchymal stem cells treatments.